AU2004201385A1 - 1,5-benzodiazepine derivatives - Google Patents

Description

AUSTRALIA

PATENTS ACT 1990 DIVISIONAL APPLICATION NAME OF APPLICANT: Glaxo Group Limited ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Nicholson Street Melbourne, 3000.

INVENTION TITLE: derivatives" The following statement is a full description of this invention, including the best method of performing it known to us: Q:\OPER\MAL\2004\DIVISIONAL\12430550 86.DOC 1/4/04 -1- Derivatives This is a divisional of Australian patent application No. 47548/00, the entire contents of which are incorporated herein by reference.

This invention relates to novel 1,5-benzodiazepine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors.

Cholecystokinin (CCK) is a peptide found in the gastrointestinal tract and the central nervous system. see A.J. Prange et al., Ann. Reports Med. Chem. 17, 31, 33 (1982), J. A. Williams, Biomed Res. 3, 107 (1982) and V. Mutt, Gastrointestinal Hormones, G.B.J. Green, Ed., Raven Press, 169. CCK has been implicated inter alia as a physiological satiety hormone involved in appetite regulation, see Della-Ferra et al, Science, 206, 471 (1979), Saito et al., Nature, 289, 599, (1981), G.P. Smith, Eating and Its Disorders, A.J. Stunkard and E. Stellar, Eds, Raven Press, New York, 67 (1984), as a regulator of gallbladder contraction and pancreatic enzyme secretion, an inhibitor of gastric emptying, and as a neurotransmitter, see A.J. Prange, supra, J.A. Williams, Biomed Res., 3, 107 (1982), J.E. Morley, Life Sci. 30, 479, (1982). Gastrin is a peptide involved in gastric acid and pepsin secretion in the stomach, see L. Sandvik, et al., American J. Physiology, 260, G925 (1991), C.W. Lin, et al., American J. Physiology, 262, G1113, (1992). CCK and gastrin share structural homology in their C-terminal tetrapeptide: Trp-Met-Asp-Phe.

Two subtypes of CCK receptors have been identified, designated as CCK-A and CCK-B, and both have been found in the periphery and central nervous systems.

It has recently been reported that CCK-B receptors are similar to the gastrin receptor, see Pisegna, de Weerth, A, Huppi, K, Wank, Biochem.

Biophys. Res. Commun. 189, 296-303 (1992). CCK-A receptors are located predominantly in peripheral tissues including the pancreas, gallbladder, ileum, pyloric sphincter and vagal afferent nerve fibers; CCK-A receptors are found to a lesser extent in the brain, see T.H. Moran, et al., Brain Res., 362, 175-179 2 (1986), D.R. Hill, et al., Brain Res, 4545, 101, (1988), D.R. Hill, et al., Neurosci Lett., 89, 133, (1988), R.W. Barret, et al., Mol. Pharmacol., 36, 285, (1989), D.R.

Hill, et al., J. Neurosci, 10, 1070 (1990), V. Dauge et al., Pharmacol Biochem Behac., 33, 637, (1989), while CCK-B receptors are found predominantly in the brain, see V.J. Lotti and R.S.L Chang, Proc. Natl. Acad. Sci. 83, 4923 (1986), J.N. Crawley, Trends Pharm. Sci., 88, 232, (1991).

CCK agonist activity has been linked to inhibition of food intake in animals and thus weight loss, see Della-Fera, et al, supra, K.E. Asin, et al, Intl. Conference on Obesity, abstract pp.40 (1990). It has been suggested that CCK acts in the periphery through vagal fibers and not directly on the brain to produce satiety, see Smith, G.P. and Cushin, Neuroscience Abstr., 4, 180 (1978), Smith, Jerome, Cushin, Eterno, and Simansky, Science, 212, 687-689, (1981).

U.S. Patent No. 5,646,140 (Sugg, et al.) discloses certain 3-amino benzodiazepine compounds which exhibit agonist activity for the CCK-A receptor thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals. See in particular, the compound of Example 7. Certain of these compounds also exhibit antagonist activity at CCK-B receptors.

Briefly, in one aspect, the present invention provides an enantiomerically enriched compound of Formula or a pharmaceutically acceptable salt or solvate thereof.

oN-, o The compound of Formula is 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4dioxo-5-phenyl-2,3,4,5-tetrahydro-1 H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid. This compound has a chiral carbon on the benzodiazepine ring.

Applicants have found that the enantiomer which rotates light in the positive direction, under the conditions described below, is preferred. This enantiomer which is hereinafter referred to as the enantiomer has the configuration according to the Cahn Ingold Prelog convention. Applicants have found that this isomer has improved properties over the racemic mixture and is therefore more suitable than the racemic mixture for the treatment of obesity and other CCK-A mediated diseases or conditions. As used herein, "enantiomerically enriched" means that there is more of the enantiomer than the enantiomer as opposed to the racemic mixture which has equal amounts of each isomer. As used herein the compound of this invention" or "the enantiomerically enriched compound of this invention", and expressions containing these or similar phrases, include pharmaceutically acceptable salts and solvates thereof. The enantiomer" refers to the optical rotation of the enantiomer and not to salts and solvates thereof. Preferred salts and solvates will be salts and solvates of the enantiomer of the compound of Formula regardless of the optical rotation of the salt or solvate.

Preferably, the enantiomer is at least %90 of the total amount of the enantiomerically enriched compound. More preferably, the enantiomer is at least %96 of the total amount of the compound. Most preferably, the enantiomer is at least %99 of the total amount of the compound.

The enantiomer of the present invention exhibits CCK-A agonist activity and can be considered a full cholecystokinin agonist in that it binds to CCK-A receptors and fully stimulates gallbladder contraction and reduces feeding in animal paradigms. For example, enantiomer of this invention should be useful for the treatment of obesity as well as related pathologies, such as hypertension, gallbladder stasis, and diabetes, indirectly through weight loss and directly through CCK-A mediated delayed gastric emptying. Moreover, the enantiomer disclosed herein provides for new approaches for inducing satiety, providing for appetite regulation and modifying food intake in mammals, especially humans, to regulate appetite, treat obesity and maintain weight loss.

Therefore, in a further aspect of the present invention, there is provided herein a method for the treatment, in a mammal, including man, of a CCK-A mediated disease or condition comprising administering to the patient a therapeutically effective amount of the enantiomer of this invention.

According to another aspect, the present invention provides the use of the enantiomerically enriched compound of this invention or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of CCK-A medicated diseases or conditions.

It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established diseases or symptoms. Moreover, it will be appreciated that the amount of the preferred enantiomer of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses employed for adult human treatment will typically be in the range of 0.02 5000 mg per day, 1-1500 mg per day. The desired dose may conveniently be presented, in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

While it is possible that the enantiomerically enriched compound of the present invention may be therapeutically administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical composition.

Accordingly, the present invention further provides for a pharmaceutical composition comprising the enantiomerically enriched compound of this invention together with one or more pharmaceutically acceptable carriers and/or excipients therefore and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) and/or excipients therefor must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Formulations of the present invention include those especially formulated for oral, buccal, parenteral, implant, topical or rectal administration, however, oral administration is preferred. For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers (for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl sulphate. The tablets may be coated according to methods well-known in the art, including enteric coatings.

Alternatively, the preferred enantiomer of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, for example. Moreover, formulations containing these the preferred enantiomer may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan monooleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives such as methyl or propyl p-hydroxybenzoates or sorbic acid.

Such preparations may also be formulated as suppositories, containing conventional suppository bases such as cocoa butter or other glycerides.

Additionally, compositions the present invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable.vehicle sterile, pyrogen-free water) before use.

The composition according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.

Accordingly, the preferred enantiorner of the invention may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins or as sparingly soluble derivatives as a sparingly soluble salt, for example.

The compositions according to the invention may contain between 0.1 99% of the active ingredient, conveniently from 30 95% for tablets and capsules, and 3 50% for liquid preparations.

The enantiomer of this invention can made by first making the racemic mixture as described in Example 7 in U.S. Patent No. 5,646,140 and then separating the enantiomers by chiral chromatography.

Alternatively the enantiomer may be prepared by reaction of the appropriate enantiomer, namely the (S)-enantiomer of the amine of formula (II); N0 olo N 0 1 with an isocyanate of formula (III; wherein R is a carboxyl protecting group e.g. tbutyl), an imidazolide of formula (IV; wherein R is a carboxyl protecting group e.g.

t-butyl) or an optionally substituted phenyl carbonate of formula wherein R is a carboxyl protecting group e.g. t-butyl and R 1 is hydrogen or a conventional phenyl substituent e.g. NO 2 followed by removal of the carboxyl protecting group R.

O=C=N-~

CO,

2

R

N

oR 0 O COR

(V)

The reaction conveniently takes place in the presence of a suitable solvent such as an ether tetrahydrofuran) or a halohydrocarbon dichloromethane) or nitrile acetonitrile) at a temperature in the range of 0-800C.

Conveniently the required enantiomer of the amine (II) may be used in the form of a salt thereof e.g. R-camphorsulphonic acid salt and in this embodiment the reaction may be carried out in the presence of a base e.g. of a tertiary amine such as triethylamine.

The hydrolysis of the carboxyl protecting group may be carried out using conventional procedures. (Protecting groups in Organic Synthesis T. Greene, Ed, Wiley Interscience, New York, p168, 1981). Thus for example when R is a t-butyl group this may be removed by hydrolysis with an appropriate acid such as hydrochloric acid, trifluoroacetic acid or formic acid using established procedures.

For example by reaction with hydrochloric acid in a solvent such as 1,4-dioxane, or by reaction with formic acid in a solvent such as acetone or aqueous acetone and with heating.

The required (S)-enantiomer of the amine of Formula (II); 0 o

NH

2

(II)

N

O

can be prepared by resolution of the corresponding racemic amine via chiral HPLC chromatography or through crystallization-induced asymmetric resolution via the R-camphorsulfonic acid salt.

The racemic amine (II) can be prepared by the method described in Intermediate 11 of US Patent No. 5,646,140.

Alternatively, the racemic amine (II) may be prepared by concomitant reduction and hydrogenolysis of the oxime (VI) wherein R 2 is an optionally substituted benzyl group.

N

0

N

N

N-OR

2 N 0

(VI)

The reaction is conveniently carried out using a suitable palladium catalyst e.g.

palladium on carbon e.g. 5% Pd/on charcoal in the presence of hydrogen or aqueous ammonium formate and in a solvent such as an aqueous alkanol e.g.

ethanol, isopropanol or industrial methylated spirits, or tetrahydrofuran.

Conveniently the reaction is carried out with heating e.g. 40-80o such as 60 0

C.

Examples of suitable R 2 groups for use in the reaction include benzyl, or substituted benzyl, such as p-methoxybenzyl, or benzhydryl.

The oxime (VI) may be prepared by reaction of the ortho-phenylene diamine derivative (VII) co

CH

2

NH

(VII)

NH

Ph with an activated derivative of the di acid (VIII) wherein R 2 is an optionally substituted benzyl group.

O R

N

HO

H

O OH o o

(VIII)

Conveniently the activated derivative of the di acid (VIII) is the corresponding diacyl halide e.g. chloride and this is prepared in situ by reaction of the di acid (VIII) with an oxalyl halide e.g. oxalyl chloride. The reaction is conveniently carried out on an aprotic solvent such as an ester e.g. ethyl acetate, toluene, dichloromethane, dimethoxyether or mixtures thereof and in the presence of dimethylformamide.

The di acid (VIII) is conveniently prepared by reaction of a di alkylketomalonate e.g. diethyl ketomalonate with the corresponding hydroxylamine R 2 0NH 2 in a solvent such as an alkanol e.g. ethanol or industrial methylated spirits and in the presence of a base e.g. pyridine, followed by hydrolysis of the corresponding di alkyl-oximino malonate using aqueous sodium hydroxide.

In a further aspect the invention provides a process for preparing the (S) enantiomer of the compound of formula substantially free of the (R) enantiomer thereof from the racemic amine (II) as described above wherein the racemic amine (II) has been prepared from the oxime (VI) as described above and more particularly, wherein the oxime (VI) has been prepared from the compounds (VII) and (VIII).

Isocyanates of Formula (I11) may be purchased or prepared by the reaction of the corresponding amine (VI) with phosgene or triphosgene in a suitable solvent such as methylene chloride. Imidazolides of Formula (IV) can be prepared by treatment of the corresponding amine (VI) with carbonyl diimidazole in a suitable solvent (dichloromethane, ether, tetrahydrofuran) at a temperature ranging from 0 800 C (conveniently at room temperature). The optionally substituted phenyl carbamates of Formula can be prepared by the reaction of the corresponding amine (VI) with the optionally substituted phenyl chloroformate in the presence of a base (pyridine, triethylamine) in a suitable solvent (dichloromethane) and at a temperature of 0 500 C. The amines of formula (VI) are either known compounds and can be prepared by procedures analogous to those used to prepare the known compounds.

The following examples, which are non-limiting, illustrate the invention.

In the Examples the abbreviations EtOAc ethyl acetate; MeOH methanol, DMF N, N-dimethylformamide; IPA isopropyl alcohol; IMS industrial methylated spirits.

Intermediate 1 (+)-2-(3-Amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo-[b][1,4]diazepin- 1-yl)-N-isopropyl-N-phenylacetamide camphorsulfonic acid salt (+/-)-2-(3-Amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo-[b][1,4]diazepin-1 yl)-N-isopropyl-N-phenylacetamide (10g) and R-camphorsulfonic acid (4.98g) were stirred in tetrahydrofuran (35ml) and toluene (65ml) to give a solution. The solution was heated to 700C with formation of a suspension. Water (0.4ml) was added followed by a solution of 2-pyridinecarboxaldehyde (0.24g) in toluene The mixture was heated at 700C for 3h and then cooled to 250C over and stirred at 250C for 16h. The suspension was chilled to 0-5C for 1.5h. The solid was collected by filtration washing with toluene/tetrahydrofuran Drying in vacuo at 50 0 C yielded the title compound as a white solid (12.6g).

Chromatographic analysis: Eluent: 30%lsopropyl Alcohol, 70% Heptane 0.05% Diethylamine; Column: 25cm x4.6mm Chiralpak AD; Flow rate: 1ml/minute; Temperature: 40 degrees C; Detection: UV 230nm; Injection volume: 10 pL; Sample solution: 0.1mg/ml; sample in 30% Isopropyl alcohol, 70% Heptane.

Sample solutions were injected immediately after preparation. Retention times: enantiomer, 8.2 minutes. The unwanted Enantiomer (12.7minutes) was below limits of detection.

Intermediate 2 3-Nitrobenzoic acid t-butyl ester Potassium t-butoxide (3.82g) was added to a solution of 3 nitrobenzoyl chloride (5.00g) in anhydrous tetrahydrofuran (70 ml) and stirred under nitrogen for 2 hrs.

The reaction mixture was concentrated in vacuo and partitioned between dichloromethane and water. After separating the phases, the aqueous layer is back-extracted with ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate, filtered and then concentrated in vacuo. The crude product was purified on flash grade silica gel using 0-5% gradient of ethyl acetate in n-hexane. Fractions containing the product were combined, concentrated in vacuo, and then dried under high vacuum to provide the title compound as an oil (3.82g). 1 H NMR (300 MHz, CDCI3) 5 1.63 9H); 7.62 (t, J=7.9 Hz, 1H); 8.29-8.41 2H); 8.78-8.80 1H). MS [M+H] 224.

Intermediate 3 3-Amino-benzoic acid t-butyl ester A solution of 3-nitro-benzoic acid t-butyl ester (3.77g), in absolute ethanol (50 ml) was combined with palladium on carbon (10 wt%, 0.30 g) and stirred under atmospheric hydrogen for approximately 3 hrs. The reaction mixture was filtered through a pad of diatomaceous earth.and then concentrated in vacuo to an oil which crystallized when dried under high vacuum providing the title compound as a tan solid (3.28g). 1 H NMR (300 MHz, CDCl3) 5 1.58 9H); 6.79-6.87 (m.

1H), 7.19 J=8.5 Hz, 1H); 7.24-7.34 1H); 7.38 J=8.0 Hz, 1H). MS (Cl): [M+H] 194.

Intermediate 4 3-Isocyano-benzoic acid t-butyl ester Triphosgene (13.428g) was added to a solution of 3-amino-benzoic acid t-butyl ester (26.50g) and triethylamine (38.23ml) in anhydrous tetrahydrofuran (600 ml) at 0-5 The reaction mixture was stirred at 0-5 °C for 2h, then concentrated in vacuo to a white solid. The crude product was slurried in hexane (500 ml), filtered, and the filtrate was concentrated in vacuo to afford the title compound as an oil (21.54 g, The crude isocyanate was used without further purification. 1 H NMR (300 MHz, CDCI 3 6= 1.59 9H); 7.23 (bd, J=7.8 Hz, 1H); 7.36 J=7.8 Hz, 1H); 7.69 (bs, 1H); 7.81 J=7.8 Hz, 1H).

Intermediate -(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid t-butyl ester Method A Intermediate 66.30g) was slowly added to a solution of 3-lsocyano-benzoic acid t-butyl ester (21.54g) in anhydrous tetrahydrofuran (750 ml). Triethylamine (13.70ml) was added dropwise to the reaction mixture. The resulting reaction mixture was stirred at ambient temperature overnight. The reaction mixture was poured into water (3000 ml) to afford a white solid. The solid was collected by filtration washing with water (3 X 500 ml). Drying by vacuum filtration yielded the title compound as a white solid (65.01g). The crude title compound was used without further purification. Chromatographic characterization: Eluent: Alcohol, 70% Heptane 0.05% Diethylamine. Column: x4.6mm Chiralpak AD; Flow rate: 1ml/minute; Temperature: 40 degrees C; Detection: UV 230nm; Injection volume: 10uL; Sample solution: 0.1mg/ml sample in 30% Isopropyl alcohol, 70% Heptane. Sample solutions were injected immediately after preparation. Retention times: enantiomer: 15.6 minutes.

The unwanted enantiomer: (13.3 minutes) was below the limits of detection.

Method B To a suspension of carbonyl diimidazole (13.2g) in dichloromethane stirring at 20°C was added dropwise a solution of 3-Amino-benzoic acid t-butyl ester (15.8g) in dichloromethane (40ml) over 30 mins. The resulting solution was stirred at 200C for 1 hour. To this solution was added a solution of Intermediate 1 (50g) in dichloromethane (130ml) over 5 minutes. The reaction was quenched by addition of water (200ml) and stirred for 10 minutes. The phases were separated and the organic phase washed with water. The organic phase was concentrated at atmospheric pressure and 100ml dichloromethane was removed by distillation.

t-Butyl methyl ether (700ml) was added and the mixture was stirred overnight at 200C. The solid was collected by filtration and washed with t-Butyl methyl ether (100ml) and dried in vacuo at 450C to provide the title compound as a white solid (42g, 63mmol).

Intermediate 6 Diethyl 2-[(benzyloxy)imino]malonate Di-ethylketomalonate (60g) was added at 20 0 C to a stirred suspension of Obenzylhydroxylamine (57.8g) in IMS (500ml) containing pyridine (30ml). The reaction was heated at 750C for 4hr. The reaction was cooled and solvents removed under reduced pressure. The residue was partitioned between EtOAc (500mi) and water (300ml) and the organic layer separated, washed with water (250ml) and dried over MgSO 4 Solvents were evaporated to give the title compound 95.3g, as a colourless oil (99%th, ca 3%w/w residual EtOAc) which was used without further purification.

1 H NMR (300MHz, CDCI 3 7.4 5H), 5.35 2H), 4.35 4H), 1.3 6H).

Intermediate 7 2-[(benzyloxy)imino]malonic acid To a solution of Intermediate 6 (40g) in MeOH (80ml) was added 2M NaOH (200ml) over 20 mins. The reaction was stirred at room temperature for 2hr.

MeOH was removed under reduced pressure and the residual solution was acidified to pH 2 by dropwise addition of conc.HCI (-30ml) while cooling to maintain the temperature below 35 0 C. A thick white slurry was formed which was diluted with water (50ml) to aid mobility. The solids were collected by filtration, washed with chilled water (25ml) and dried in vacuo at 55 0 C to give the title compound as a white solid (17g) found to contain ca.10%w/w residual inorganic salts. Corrected yield 45%th. Used without further purification.

1H NMR (300MHz, D 2 0) 7.4 5H), 5.2 2H) Intermediate 8 2 3 -[(Benzyloxy)imino]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5benzodiazepinyl)-N-isopropyl-N-phenylacetamide Oxalyl chloride (38.3g) was added dropwise (-lhr) to a stirred suspension of Intermediate 7 (40g, corrected for salt content to 31.4g) in EtOAc (200ml) containing DMF (0.5ml, 5 mol%). The mixture was stirred at 25 0 C for 0.5 hour then filtered through a pad of Dicalite, washing with EtOAc (40ml) to give a clear yellow solution. The solution was added (-5mins) to a stirred slurry of Nisopropyl-N-phenyl-2-(2-phenylaminophenylamino)-acetamide (50g) in EtOAc (120ml) at 25C. The mixture was warmed to 600C and a dark purple solution formed. After 1hr, EtOAc (200ml) was removed by atmospheric distillation. IPA (120ml) and water (40ml) were added and the mixture distilled further to remove more solvent (80ml). IPA (40ml) and water (40ml) were added and a further amount of solvent was distilled out (80ml). The reaction mixture was cooled to OC over 1.5hr and the solids collected by filtration. The solids were washed with IPA (2 x 120 ml), water (1 x 120ml) and finally IPA again (1 x 40ml) then dried in vacuo at 55 0 C to give the title compound as a salmon pink powder (56.6g).

1H NMR (300MHz, CDCI 3 2:1 mixture of isomers about the oxime 7.6-6.95 (m.

18H), 6.9 (t 1H), 5.3 2H), 4.95 4.65 0.33H), 4.4 0.67H), 4.1 0.67H), 4.0 0.33H), 0.95 6H) Intermediate 9 2 3 -Amino- 2 ,4-dioxo-5-phenyl-2,3,4,5-tetrahydrobenzo-[b][1,4]diazepen- 1-yl)-N-isopropyl-N-phenylacetamide To a stirred suspension of Intermediate 8 (3g) and ammonium formate (2.08g) in IMS (30ml) and water (3ml) was added 5% Pd/C (50% w/w water) (0.25g). The mixture was heated under a nitrogen atmosphere at 600C overnight. The hot reaction mixture was filtered through Dicalite to remove the catalyst. The catalyst was washed with hot IMS (60ml) and filtered. The filtrates were concentrated under reduced pressure to give the title compound as a white solid (2.34g).

Example 1 Chromatographic Resolution of Enantiomers and (-)-3-{3-[1-(lsopropyl-phenyl-carbamoylmethyl)-2,4-dioxo.5-phenyl- 2,3,4,5-tetrahydro-1 H-benzo[b]l 1, 4 ]diazepine-3-yl]-ureido} benzoic acid.

Racemic 3-{3-[1-(lsopropyl-phenyl-carbamoylmethyl)-2, 4 -dioxo-5-phenyl-2,3,4,5tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid was prepared as described for example 7 in U.S. Patent No. 5,646,140 and resolved by chiral HPLC under the following conditions: a 250 x 4.0 pm (id) column, 5um Diacel Chiracel OD-R; the eluent was 80:20:0.1:1, 80 parts acetonitrile, 20 parts water, 0.1 part triethylamine, and 1 part acetic acid; the UV detection wavelength was 230nm; the temperature was ambient; the flow rate was lml/min; and the injection volume was 20ul. Under these conditions the enantiomer had a retention time of 6.50 minutes and the isomer had a retention time of 3.89 minutes.

Example 2 (+)-3-{3-[1-(lsopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-.5phenyl-2,34,5.

tetrahydro-1 H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid Method A -(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid t-butyl ester (Intermediate ambient temp the resulting solid was col! product was until the solt.

solution wa aside and washed wi: 40-50 0 C t purity by Optical rot DMSO) 6= 1H); 4.48 Hz, 1H); 6 12.78 1 5: 65.01g) was stirred in 4N hydrochloric acid in dioxane (280 ml) at e: t:ure for 6h. The reaction mixture was concentrated in vacuo and s /,oil was triturated in water to afford a white solid. The white d by filtration and washed with water (2 X 500 ml). The crude )lved in hot acetone (250 ml) and water (275 ml) was added oecame cloudy. Additional acetone (40 ml) was added and the ited until a clear solution was obtained. The solution was set -d to cool. The resulting white solid was collected by filtration :er (3 X 100 ml) and dried under house vacuum (20-25 in Hg) at vide the title compound as a white solid (40.496g). Analyzed for 31 chromatography (see chromatographic resolution protocol).

1 (0.712g in 100mL acetone) +84.3. 'H NMR (300 MHz, J=7.5 Hz, 3H); 0.97 J=7.2 Hz, 3H); 4.18 J=16.7 Hz, J=16.7 Hz, 1H); 4.78 1H); 5.02 J=7.8 Hz, 1H); 6.91 J=7.8 (bd, J=8.1 Hz, 1H); 7.22-7.57 19H); 8.00 1H); 9.34 1H); MS 606.1; [M+Na] 628.1; 604.1.

Method B Intermediate 5 was added to a mixture of acetone (15ml) and formic acid at room temperature and the resulting suspension was heated to and stirred for 5h. Water (30ml) was added dropwise to the solution ensuring the contents temperature was kept above 500C. The resultant slurry was stirred at 550C for 1h, cooled to room temperature and stirred overnight. The slurry was filtered and washed with water (3x25ml). The residue was added to IMS and the slurry was heated to 450C and stirred overnight. The slurry was cooled to room temperature, filtered and the damp cake was dried in vacuo at 550C to the title compound as a white solid (3.40g).

Chiral chromatographic analysis showed that the required product of the reaction contained 0.7% of the unwanted enantiomer.

Pharmacy Examples Oral solution Active ingredient 0.5-800 mg Polyethylene glycol 400 NF q.s. to 50 ml The active ingredient is suspended in Polyethylene glycol 400 and is then dissolved by sonication to produce the oral solution.

Oral suspension Active ingredient 0.5-80 mg Polysorbate 80 NF (Tween 80) 0.02 ml Sterile Water for Irrigation q.s. to The active ingredient is added to a 0.1% Tween 80 solution (20 ml) and the mixture is then sonicated or shaken to produce the oral suspension.

Tablets a. Active ingredient 6mg Lactose anhydrous USP 136.2mg Sodium Starch Glycolate USP/NF 6mg Stearic Acid USP/NF Colloidal Silicon Dioxide USP/NF 0.3mg Compression weight 150mg The active ingredient, lactose, and sodium starch glycolate are sieved through a 590 micron sieve and blended in a suitable mixer. Stearic acid (screened through a 250 micron sieve) and colloidal silicon dioxide are added to and blended with the active blend. The blend is compressed into tablets using suitable punches.

b. Active ingredient 6mg Microcrystalline cellulose USP/NF 136.5mg Crospovidone USP/NF 6mg Magnesium stearate USP/NF Compression weight 150mg The active ingredient, microcrystallline cellulose and crospovidone are sieved through a 590 micron sieve and blended in a suitable blender. The magnesium stearate is screened (through a 250 micron sieve) and blended with the active blend. The resultant blend is compressed into tablets using suitable tablet punches.

Capsules a. Active ingredient 6mg Microcrystalline cellulose USP/NF 128.25mg Sodium starch glycolate USP/NF Magnesium stearate USP 0.75mg Fill weight 150mg The active ingredient, microcrystalline cellulose, and sodium starch glycolate are screened through a 590 micron mesh sieve, blended together and lubricated with magnesium stearate, that has been screened through a 250 micron sieve. The blend is filled into capsules of a suitable size.

b. Active ingredient 6mg Lactose monohydrate USP 130.5mg Povidone USP 6mg Crospovidone NF 6mg Magnesium stearate Fill weight 150mg The active ingredient and lactose are blended together and granulated with a solution of Povidone. The wet mass is dried and milled. The magnesium stearate and Crospovidone are screened through a 250 micron sieve and blended with the granule. The resultant blend is filled into hard gelatin capsules of a suitable size.

BIOLOGICAL ASSAYS The and (-)-enantiomers and the racemic mixture were characterized in the following assays. The results of these assays are summarized in the table below.

Guinea Pig Gallbladder Tissue Preparation. Gallbladders were removed from male Hartley guinea pigs sacrificed with CO2 atmosphere. The isolated gallbladders were cleaned of adherent connective tissue and cut into two rings from each animal (2-4 mm in length). The rings were suspended in organ chambers containing a physiological salt solution (118.4 mM NaCI, 4.7 mM KCI, 1.2 mM MgSO4, 2.5 mM CaCI2, 1.2 mM KH2PO3, 25 mM NaHCO3 11.1 mM dextrose). The bathing solution was maintained at 370C and aerated with 02/5% C02 to maintain pH 7.4. Tissues were connected via gold chains and stainless steel mounting wires to isometric force displacement transducers (Grass, Model FT03 Responses were then recorded on a polygraph (Grass, Model 7E). One tissue from each animal served as a time/solvent control and did not receive test compound. Rings were gradually stretched (over a 120-min.

period) to a basal resting tension of 1 gm which was maintained throughout the experiment. During the basal tension adjustment period, the rings were exposed to acetylcholine (10- 6 M) four times to verify tissue contractility. The tissues were then exposed to a submaximal dose of sulfated CCK-8 (Sigma, 3 X 10- 9

M).

After obtaining a stable response, the tissues were washed out 3 times rapidly and every 5 to 10 minutes for 1 hour to reestablish a stable baseline.

Agonist EC50's. Compounds were dissolved in dimethylsulfoxide (DMSO) then diluted with water and assayed via a cumulative concentration-response curve to test compound (10- 1 1 to 3 X 10- 5 M) followed by a concentration-response curve to sulfated CCK-8 (10- 1 0 to 10-6 M) in the presence of the highest concentration of the test compound. As a final test, acetylcholine (1 mM) was added to induce maximal contraction. A minimum of three determinations of activity were made for each test compound.

Establishment of stable CCK receptor bearing cell lines. The cDNA clones for the human CCK-A 1 8 or CCK-B 1 9 receptors were ligated into pcDNA1-Neo vector from Invitrogen Corp (San Diego, CA) for direct transfection. DNA was prepared by the alkaline lysis method and transfected into CHO-K1 cells (ATCC, Rockville, MD) using the Lipofectin reagent 2 4 (Gibco BRL, Gaithersberg, MD).

Stable transfectants were initially selected by the use of Geneticin (Gibco BRL) and receptor bearing resistant cells were enriched by fluorescence-activated cell sorting based on binding of Fluorescein-Gly-[(Nle28,31]-CCK-8. Clonal lines were subsequently established by the limiting dilution method.

Cell Membrane Preparation. CHO-K1 cells stably transfected with human CCK-A or CCK-B receptor cDNA were grown at 37oC under a humidified atmosphere (95% 02/5% C02) in Ham's F12 medium supplemented with heat inactivated fetal bovine serum. The cells were passaged twice weekly and grown to a density of 2-4 million cells/mL. The cells were collected by centrifugation (600 X g, 15 min, 4 oC) and resuspended in buffer (20 mL, pH 7.4) containing TrisHCI (25 mM), EDTA (5 mM), EGTA (5 mM), phenyl sulfonyl fluoride (0.1 mM) and soybean trypsin inhibitor (100 pg/mL). Cells were disrupted with a motorized glass teflon homogenizer (25 strokes) and the homogenate was centrifuged at low speed (600 X g, 10 min, 40C). The supernatent was collected and centrifuged at high speed (500,000 X g, 15 min to pellet the particulate fraction. The low speed pellet was processed three additional times. High-speed particulate fractions were combined and resuspended in buffer (1-5 mg protein/mL) and frozen at -800C. Protein concentration was determined according to manufacturer's directions using BioRad reagent and bovine serum albumin as standard.

Receptor Binding Assays. 1 2 5 1-Bolton Hunter CCK-8 (Amersham, 2000 Ci/mmol) was dissolved in binding buffer (pH 7.4, 100,000 cpm/25 pL) containing HEPES (20 mM), NaCI (118 mM), KCI (5 mM), MgCl2 (5 mM) and EGTA (1 mM).

Nonspecific binding was determined with MK-329 2 0 (10 lM, CCK-A) or L- 365,26021 (10 piM, CCK-B). Test compounds were dissolved in DMSO at a stock concentration of 100 times the final assay concentration and diluted to appropriate concentrations with binding buffer. Binding assays were performed in triplicate using 96-well plates to which the following were added sequentially: test compound (25 pL), 1 2 5 1-Bolton Hunter CCK-8 (25 pL), buffer (pH 7.4, 150 PiL) and receptor preparation (50 The final concentration of DMSO was 1% in all assay wells. After 3 hours at 300C, the incubation was terminated by rapid filtration of the mixture onto glass filters (Whatman GF/B) with subsequent washing to remove unbound ligand. Bound radioactivity was quantified by gamma counting.

Intracellular Calcium Measurements: CHO-K1 cells stably transfected with hCCK-A or hCCK-B receptors were grown on glass coverslips to 75-90% confluency. The cells were loaded for 50 minutes in serum-free culture medium containing 5 mM FURA2-AM and 2.5 mM probenecid. A JASCO CAF-102 calcium analyzer was used to measure changes in intracellular calcium concentration by standard ratiometric techniques using excitation wavelengths of 340 nm and 380 nm. Cells were perfused with increasing concentrations of CCK- 8 (n 2) or compounds (n 2) until a plateau in the 340/380 ratio was achieved.

A washout/recovery period of at least 10 minutes was allowed between successive stimulations. The maximal response was normalized to the maximal response induced by CCK-8. EC50's were calculated at the concentration required to induce half-maximal response. In addition to the agonist concentration-response curves, the CHO-K1 cells expressing the human CCK-B receptor were perfused for 1 hour with three concentrations of compounds (10- 8 7 10- 6 M, n then a concentration response curves were acquired for CCK-8 (10- 1 2 to 10 6

M).

Anorexia Assays: Male Long-Evans rats (225-300 g) were conditioned for two weeks to consume a palatable liquid diet (Bio-Serve F1657, Frenchtown, NJ) after a 2 hr fast. On pretreatment day, rats were fasted (100 min) and injected IP with drug vehicle (propylene glycol, PG, 1 mUkg) and an oral preload of saline NaCI, 8 mL/kg). Liquid diet access was provided 20 min later and consumption was measured at 30, 90 and 180 min. To qualify for the drug treatment study, rats had to consume at least 8 mL of liquid diet within the first minutes on the pretreatment day. The next day, following the 100 min deprivation, rats (8 10 animals per dose) were treated IP or PO with vehicle (PG, 1 mL/kg) or various doses (0.01 to 10 imol/kg) of test compound dissolved in PG (1 mL/kg), immediately followed by the saline oral preload. Food access was again provided 20 min later and food intake was measured at 30, 90 and 180 min. All food intake data were normalized for each rat to the respective values from the pretreatment day. Potency was determined at 30 min and efficacy at the min, 1 pjmol/kg dose.

Mouse gallbladder emptying assay: Makovec, Bani, Cereda, R.; Chiste, Pacini, M. Revel, Rovati, L. C. Antispasmodic Activity on the Gallbladder of the Mouse of CR1409 (Lorglumide), a Potent Antagonist of Peripheral Chlolecystokinin. Pharmacol. Res. Commun. 1987, 19, 41-51.

24 PApp values: A measurement of intestinal permeation determined using the in vitro assay of Artursson P. and Karlson J. 1991, Biochem. Biophys Res.

Common.175, 880-885 (Correlation between oral drug absorption in humans and apparent drug permeability co-efficients in human intestinal epithelical (CACO-2) cells).

Pharmacological Comparison of Enantiomers Racemate Assay Enantiomer Enantiomerin vitro____ __I GPGB EC 50 (nM) 9. 63 HCCK-A IC50 (nM) 148 191 HCCK-A EC 50 o (nM) 150 2 98 HCCK-13 Ki (nM) 22.3 HCCK-B ECsio(nM) Antagonist Antago nist Selectivity Ratio' 46 8.6 PApp (x 10-' cm/sec) 4 1 in vivoII Racemnate 123 252 .Antagonist 12.3 0.7 0.06 0.007 0.055 Rat Anorexia

ED

50 IP (pj-inol/kg)

ED

50 P0 (ii. fbi/kg) Mouse Gallbladdje-r 0.034 0.48 Inactive" 0.012 Emptying Assay

ED

50 IP (P..Molkg). 0.002

ED

50 PO .imol/kg) 0.007 I Inactive 1. Selectivity ratio IC50 (hCCK-A)fKi (hCCK-B) 2. Inactive up to 10 p.mol/kg 3. No significant reduction in feeding observed with doses up to lOpmol/kg.

Three unexpected biological activities distinguish the enantiomer from the enantiomer and the racemate. Two of these activities relate to enhanced CCK-A efficacy, which should improve the beneficial activity of this enantiomer. The third relates to the CCK-B antagonist activity of the enantiomer which should prove beneficial through decreased toxicity.

The enantiomer was four-fold more potent than the racemate in the in vitro isolated guinea pig gallbladder test The enantiomer was eight-fold more potent than the racemate in the mouse gallbladder emptying assay (oral dosing). This increased potency is expected to be beneficial in the treatment of gallbladder stasis and in the treatment of obesity, since gallbladder stasis is a critical problem with rapid weight loss.

Anorectic agents are intended for chronic use and thus it is essential that they possess minimal risk for toxicity. The primary toxicity associated with the use of cholecystokinin is concomitant CCK-B receptor agonist activity. ctivation of the CCK-B receptor is primarily associated with increased anxiety and increased gastric acid secretion. The utility of CCK-B antagonists have been explored for both the development of anxiolytic agents and anti-ulcer agents. See, for example, Lowe, J, "Cholecystokinin-B Receptor Antagonists" in Exp. Opin. Ther.

Patents, pp 231-237 (1995).

The predominant CCK receptor subtype in the rodent pancreas is the CCK-A subtype and activation of this subtype induces pancreatic hyperstimulation and hypertrophy in rodents. Both of these activities are considered to be undesirable.

Recently, the tissue distribution of CCK receptors in human tissues has been reported. Surprisingly, the predominate receptor subtype in human pancreas is the CCK-B receptor subtype. See, for example, Wank, S. "Cholecystokinin Receptors" in American Journal of Physiology Gastrointestinal Liver Physiology, pp G628-G646, (1995). rThus, in humans, activation of the CCK-B receptor (CCK-B agonist activity) could induce increased anxiety and gastric acid secretion, as well as pancreatic hyperstimulation and hypertrophy with long term use.

In order to decrease the risk of undesirable in vivo CCK-B agonist activity, the preferred compound should have affinity for the CCK-B receptor and have measurable CCK-B antagonist activity in in vitro assays. Both enantiomers and the racemate are CCK-B antagonists. Although all three compositions have similar human CCK-A receptor affinities (IC50) and efficacies (EC50), the enantiomer has the highest CCK-B receptor affinity (1C50) and selectivity (46fold). Thus, the enantiomer is preferred both in terms of CCK-A potency and efficacy, as well as in terms of the minimal potential for CCK-B induced toxic side effects.

The enantiomer of the invention is essentially non-toxic at therapeutically useful doses. For example, in single dose oral studies the maximum non-lethal dose was found to be greater than 2000mg/kg in the rat and 1000mg/kg for male mice and 500mg/kg for female mice.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Claims (12)

1. Enantiomerically enriched 3-{3-[1-(lsopropyl-phenyl-carbamoylmethyl)-2,4- dioxo-5-phenyl-2,3,4,5-tetrahydro-1 H-benzo[b][1,4]diazepine-3-yl]- ureido)benzoic acid, or a pharmaceutically acceptable salt or solvate thereof.

2. The enantiomerically enriched compound of Claim 1 wherein the enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 90% of said compound.

3. The enantiomerically enriched compound of Claim 1 or claim 2 wherein the enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 99% of said compound.

4. A pharmaceutical composition comprising the enantiomerically enriched compound as claimed in any one of claims 1 to 3 in admixture with one or more pharmaceutically acceptable carriers and or excipients.

5. A method for treating a CCK-A mediated disease or condition comprising administration of an effective amount of compound, as claimed in any one of claims 1 to 3.

6. A method for treating a CCK-A mediated disease or condition comprising administration of the pharmaceutical composition as claimed in Claim 4.

7. The method as claimed in claim 5 or claim 6, wherein said disease or condition is obesity, gallbladder stasis, or diabetes.

8. The method as claimed in claim 5 or claim 6, wherein said disease or condition is obesity. P:\OPER~Mal\2004\ 2430550 claims doc-26/03/04 29

9. The use of a compound as claimed in any one of claims 1 to 3 in the manufacture of a medicament for the treatment of a CCK-A mediated disease or condition.

A process for the preparation of a compound as claimed in claim 1 which comprises: resolution of racemic 3-[3-[1-(isopropyl-phenyl-carbamoylmethyl)- 2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1 H-benzo[b][1,4]diazepine-3- yl]benzoic acid by chiral hplc; reaction of the appropriate enantiomer of the amine of formula (II), N N NH 2 (J) With the isocyanate of formula (III), imidazolide of formula (IV) or optionally substituted phenyl carbamate of formula followed by removal of the carboxy protecting group R. P \OPERWM.h2OO4\243OS55 dI a. sdc-2,/03fP4 30 Cc 2 R CO,R 0 C) N MCR H (V)

11. A process as claimed in claim 10 wherein the required compound of claim 1 is prepared via the racemic amine (11) which has been prepared by concomitant reduction and hydrogenolysis of the oxime (VI), 0 1 0 N-OR, (V) wherein R 2 is an optionally substituted benzyl group. P OpCAM I2004\I 2430550 claimI dC-0 1104104 31

12. A process as claimed in claim 11 wherein the oxime (VI) is prepared from the ortho phenylene diamine (VII) and an activated derivative of the diacid (VIII), N -OR, N CO HO CH, NH 0 0 (VII) NH Ph wherein R 2 is an optionally substituted benzyl group. DATED this 1 st day of April, 2004 Glaxo Group Limited By DAVIES COLLISON CAVE Patent Attorneys for the Applicants